Jasper Therapeutics Stock Today
| JSPR Stock | USD 3.33 0.04 1.19% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Jasper Therapeutics is selling at 3.33 as of the 19th of July 2025; that is 1.19 percent decrease since the beginning of the trading day. The stock's lowest day price was 3.26. Jasper Therapeutics has about a 26 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of September 2021 | Category Healthcare | Classification Health Care |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company has 15.02 M outstanding shares of which 1.29 M shares are currently shorted by private and institutional investors with about 6.99 trading days to cover. More on Jasper Therapeutics
Moving against Jasper Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Jasper Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Ronald Martell | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsJasper Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Jasper Therapeutics' financial leverage. It provides some insight into what part of Jasper Therapeutics' total assets is financed by creditors.
| |||||
Jasper Therapeutics (JSPR) is traded on NASDAQ Exchange in USA. It is located in 2200 Bridge Pkwy, Redwood City, CA, United States, 94065 and employs 64 people. Jasper Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 50.02 M. Jasper Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 15.02 M outstanding shares of which 1.29 M shares are currently shorted by private and institutional investors with about 6.99 trading days to cover.
Jasper Therapeutics currently holds about 60.81 M in cash with (62.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.6.
Check Jasper Therapeutics Probability Of Bankruptcy
Ownership AllocationJasper Therapeutics has a total of 15.02 Million outstanding shares. The majority of Jasper Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Jasper Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Jasper Therapeutics. Please pay attention to any change in the institutional holdings of Jasper Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Jasper Ownership Details
Jasper Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2025-03-31 | 534.6 K | |
| Kingdon Capital Management Llc | 2025-03-31 | 490 K | |
| Citadel Advisors Llc | 2025-03-31 | 375.2 K | |
| Bank Of America Corp | 2025-03-31 | 360.7 K | |
| Geode Capital Management, Llc | 2025-03-31 | 263.7 K | |
| Goldman Sachs Group Inc | 2025-03-31 | 233.8 K | |
| State Street Corp | 2025-03-31 | 227.9 K | |
| Deutsche Bank Ag | 2025-03-31 | 169.3 K | |
| Lion Point Capital, Lp | 2025-03-31 | 146.5 K | |
| Soleus Capital Management, L.p. | 2025-03-31 | 1.5 M | |
| Velan Capital Investment Management Lp | 2025-03-31 | 1.4 M |
Jasper Therapeutics Historical Income Statement
Jasper Stock Against Markets
Jasper Therapeutics Corporate Management
| Kimberly Baxter | VP Quality | Profile | |
| Luca Noto | Senior Operations | Profile | |
| Carol Zoltowski | VP Quality | Profile | |
| Jeetinder MBA | Chief Officer | Profile |
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.